Sugi Predict

Sugi Predict / Compounds / SCHEMBL215721

SCHEMBL215721

SCHEMBL215721

CC(C)(C)OC(=O)N1CCC[C@@H](OS(C)(=O)=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HPGD P15428 1/20 0.47
▸ PRMT5 O14744 1/20 0.43
▸ WDR77 Q9BQA1 1/20 0.43
▸ EPHX1 P07099 1/20 0.42
▸ SCN9A Q15858 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ GPR119 Q8TDV5 3/20 0.41
▸ USP30 Q70CQ3 2/20 0.40
▸ PREP P48147 1/20 0.40
▸ CHEK2 O96017 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MMP1 P03956 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ JAK2 O60674 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215720 1.00 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL731800 1.00 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL9938442 0.96 HPGD (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31045719 0.94 HPGD (0.51) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL66145 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL330785 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL66134 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL4008565 0.89 HPGD (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL29981135 0.89 HPGD (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL5538557 0.86 GPR119 (0.45) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 — — EP disclosed
WO-2025202889-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-10-02 — — WO disclosed
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 — — US disclosed
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-08-28 — — US disclosed
US-12351581-B2 Compounds for FGFR inhibition COGENT BIOSCIENCES, INC. (US) 2025-07-08 — — US disclosed
WO-2025034912-A9 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-04-24 — — WO disclosed
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-02-27 — — US disclosed
WO-2025034912-A2 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-02-13 — — WO disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 — — EP disclosed
US-12084445-B2 Broad-spectrum carbapenems VenatoRx Pharmaceuticals, Inc. (US) 2024-09-10 — — US disclosed
US-20050131023-A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) 2005-06-16 — — US disclosed
WO-2005021095-A2 TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-03-10 — — WO disclosed
EP-1501495-A1 USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI Sandoz AG (CH) 2005-02-02 — — EP disclosed
EP-1492518-A2 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES Sandoz AG (CH) 2005-01-05 — — EP disclosed
US-20040102482-A1 Antibacterial Mutilins Nabriva Therapeutics GmbH (AT) 2004-05-27 — — US disclosed
EP-1320525-B1 ANTIBACTERIAL MUTILINS BIOCHEMIE GMBH (AT) 2004-04-21 — — EP disclosed
WO-2003090740-A1 USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI SANDOZ AG (CH) 2003-11-06 — — WO disclosed
WO-2003082260-A2 TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES SANDOZ AG (CH) 2003-10-09 — — WO disclosed
EP-1320525-A1 ANTIBACTERIAL MUTILINS BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2003-06-25 — — EP disclosed
WO-2002022580-A1 ANTIBACTERIALS MUTILINS BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131023-A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori FABP6, PLEC, UBQLN2 MEN1 626/4885ALDH1A1 979/4885MAPT 3998/4885
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 MEN1 2019/4885ALDH1A1 1423/4885MAPT 90/4885
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 MEN1 2019/4885ALDH1A1 1423/4885MAPT 90/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 MEN1 2177/4885ALDH1A1 2210/4885MAPT 1555/4885
US-12351581-B2 Compounds for FGFR inhibition FGFR1, FGFR4, FGFR3 MEN1 2019/4885ALDH1A1 1423/4885MAPT 90/4885
US-20040102482-A1 Antibacterial Mutilins MRPS27, MRPS18B, MRPS22 MEN1 2686/4885ALDH1A1 1691/4885MAPT 4676/4885
US-12084445-B2 Broad-spectrum carbapenems MGAM, ALPI, SI MEN1 3883/4885ALDH1A1 3603/4885MAPT 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.